TY - JOUR
T1 - Therapeutic guide for mTOuRing through the braided kidney cancer genomic river
AU - Voss, Martin H.
AU - Hsieh, James J.
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/5/15
Y1 - 2016/5/15
N2 - mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/ phenotypes beyond genes in kidney cancer, like a braided river.
AB - mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/ phenotypes beyond genes in kidney cancer, like a braided river.
UR - http://www.scopus.com/inward/record.url?scp=84968756959&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-0035
DO - 10.1158/1078-0432.CCR-16-0035
M3 - Article
C2 - 26920890
AN - SCOPUS:84968756959
SN - 1078-0432
VL - 22
SP - 2320
EP - 2322
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -